Alexander Schmittel

5.3k total citations · 1 hit paper
100 papers, 3.5k citations indexed

About

Alexander Schmittel is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alexander Schmittel has authored 100 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 32 papers in Molecular Biology and 30 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alexander Schmittel's work include Immunotherapy and Immune Responses (27 papers), Lung Cancer Research Studies (22 papers) and Ocular Oncology and Treatments (19 papers). Alexander Schmittel is often cited by papers focused on Immunotherapy and Immune Responses (27 papers), Lung Cancer Research Studies (22 papers) and Ocular Oncology and Treatments (19 papers). Alexander Schmittel collaborates with scholars based in Germany, United States and Netherlands. Alexander Schmittel's co-authors include Ulrich Keilholz, Carmen Scheibenbogen, Eckhard Thiel, Anne Letsch, Dirk Nagorsen, E. Thiel, Nikolaos E. Bechrakis, Martin Sebastian, Ingeborg Tinhofer and Peter Martus and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Alexander Schmittel

97 papers receiving 3.5k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

2010 405 citations Alexander Schmittel, Horst Lindhofer et al. International Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alexander Schmittel Germany	36	1.9k	1.4k	1.1k	567	450	100	3.5k
Adi Diab United States	38	4.0k 2.1×	2.0k 1.4×	779 0.7×	923 1.6×	517 1.1×	194	5.2k
Gerhard Fierlbeck Germany	30	1.2k 0.6×	793 0.6×	813 0.8×	458 0.8×	514 1.1×	97	3.2k
Maresa Altomonte Italy	36	2.1k 1.1×	1.7k 1.2×	1.6k 1.5×	856 1.5×	164 0.4×	95	4.4k
Jason Konner United States	31	1.8k 0.9×	910 0.7×	889 0.8×	525 0.9×	317 0.7×	122	4.0k
Mauro Truini Italy	27	948 0.5×	825 0.6×	677 0.6×	468 0.8×	189 0.4×	101	2.6k
Xavier Sastre France	33	2.0k 1.0×	618 0.4×	822 0.8×	1.5k 2.6×	237 0.5×	77	4.2k
Luana Calabrò Italy	30	2.3k 1.2×	1.0k 0.7×	1.4k 1.3×	1.5k 2.7×	197 0.4×	111	4.4k
Gal Markel Israel	41	2.5k 1.3×	3.0k 2.1×	1.5k 1.4×	354 0.6×	509 1.1×	126	5.8k
Patrick Terheyden Germany	23	2.8k 1.5×	815 0.6×	606 0.6×	381 0.7×	398 0.9×	107	3.4k
Pascale Mariani France	29	1.3k 0.7×	338 0.2×	731 0.7×	444 0.8×	224 0.5×	108	2.8k

Countries citing papers authored by Alexander Schmittel

Since Specialization

Citations

This map shows the geographic impact of Alexander Schmittel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Schmittel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Schmittel more than expected).

Fields of papers citing papers by Alexander Schmittel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Schmittel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Schmittel. The network helps show where Alexander Schmittel may publish in the future.

Co-authorship network of co-authors of Alexander Schmittel

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Schmittel. A scholar is included among the top collaborators of Alexander Schmittel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Schmittel. Alexander Schmittel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kollmeier, Jens, Alexander Schmittel, B. Schmidt, et al.. (2019). Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population. Annals of Oncology. 30. v615–v615. 2 indexed citations

Ludwig, Wolfgang, et al.. (2017). A Patient with Non‐Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy. Case Reports in Oncological Medicine. 2017(1). 5640186–5640186. 2 indexed citations

Köhler, Christhardt, Peter Oppelt, Giovanni Favero, et al.. (2015). How much platinum passes the placental barrier? Analysis of platinum applications in 21 patients with cervical cancer during pregnancy. American Journal of Obstetrics and Gynecology. 213(2). 206.e1–206.e5. 47 indexed citations

Schuster, R., Nikolaos E. Bechrakis, Andrea Stroux, et al.. (2011). Prognostic Relevance of Circulating Tumor Cells in Metastatic Uveal Melanoma. Oncology. 80(1-2). 57–62. 24 indexed citations

Liu, Zhian, Alberto Fusi, Alexander Schmittel, et al.. (2010). Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine. Cancer Biology & Therapy. 10(9). 860–864. 24 indexed citations

Schuster, R., Frank Wacker, Nikolaos E. Bechrakis, et al.. (2010). Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Research. 20(3). 191–196. 35 indexed citations

Marnitz, Simone, Christhardt Köhler, Peter Oppelt, et al.. (2010). Cisplatin Application in Pregnancy: First in vivo Analysis of 7 Patients. Oncology. 79(1-2). 72–77. 44 indexed citations

Schmittel, Alexander, Martin Sebastian, Ludwig Fischer von Weikersthal, et al.. (2009). Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: Results of the German randomized phase III trial. Journal of Clinical Oncology. 27(15_suppl). 8029–8029. 8 indexed citations

Schmittel, Alexander, Ursula Steiner, Anne Marie Asemissen, et al.. (2009). Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib. Oncology. 76(5). 350–354. 69 indexed citations

10.

Sebastian, Martin, Philipp Kiewe, Wolfgang Schuette, et al.. (2009). Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM×Anti-CD3). Journal of Immunotherapy. 32(2). 195–202. 44 indexed citations

11.

Sebastian, Martin, et al.. (2009). Catumaxomab: A bispecific trifunctional antibody. Drugs of today. 45(8). 589–589. 32 indexed citations

12.

Busse, Antonia, Gero Hütter, Jan Siehl, et al.. (2007). A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high grade non-Hodgkins lymphoma. Leukemia & lymphoma. 48(9). 1755–1763.

13.

Gridelli, Cesare, E. Kaukel, Vanesa Gregorc, et al.. (2007). Single-Agent Pemetrexed or Sequential Pemetrexed/Gemcitabine as Front-Line Treatment of Advanced Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy: A Multicenter, Randomized, Phase II Trial. Journal of Thoracic Oncology. 2(3). 221–229. 35 indexed citations

14.

Schmittel, Alexander, M. E. Scheulen, Nikolaos E. Bechrakis, et al.. (2005). Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Research. 15(3). 205–207. 40 indexed citations

15.

Jahnke, Kristoph, Agnieszka Korfel, Peter Martus, et al.. (2005). High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Annals of Oncology. 16(3). 445–449. 87 indexed citations

16.

Letsch, Anne, Ulrich Keilholz, Michael Fluck, et al.. (2005). Peptide vaccination after repeated resection of metastases can induce a prolonged relapse‐free interval in melanoma patients. International Journal of Cancer. 114(6). 936–941. 10 indexed citations

17.

Schmittel, Alexander, et al.. (2004). Phase I Dose Escalation Study of Carboplatin to a Fixed Dose of Irinotecan as First-Line Treatment of Small Cell Lung Cancer. Oncology Research and Treatment. 27(3). 280–284. 8 indexed citations

18.

Scheibenbogen, Carmen, Dirk Schadendorf, Nikolaos E. Bechrakis, et al.. (2003). Effects of granulocyte‐macrophage colony‐stimulating factor and foreign helper protein as immunologic adjuvants on the T‐cell response to vaccination with tyrosinase peptides. International Journal of Cancer. 104(2). 188–194. 57 indexed citations

19.

Bechrakis, Nikolaos E., et al.. (2002). Aderhautmelanom Adjuvante Therapie bei Hochrisikopatienten und neue Therapieansätze im metastasierten Stadium. Der Ophthalmologe. 99(5). 333–337. 5 indexed citations

20.

Nagorsen, Dirk, Ulrich Keilholz, Licia Rivoltini, et al.. (2000). Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.. PubMed. 60(17). 4850–4. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact